Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.49 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.49 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785681 | 1.00 | TDO2 (0.55) | TDO2ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL3490386 | 0.87 | TDO2 (0.54) | TDO2ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL2020140 | 0.86 | ABL1 (0.59) | TDO2ADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL28255761 | 0.85 | TDO2 (0.55) | TDO2ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL1271676 | 0.85 | ALDH1A1 (0.56) | TDO2ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL13211663 | 0.82 | ABL1 (0.60) | TDO2ADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL3455245 | 0.82 | ABL1 (0.60) | TDO2ADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL6571024 | 0.82 | CYP3A4 (0.58) | TDO2ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL6011438 | 0.82 | CYP3A4 (0.58) | TDO2ADORA2AADORA1ALDH1A1HSD17B10 | |
| SCHEMBL227526 | 0.82 | CYP11B2 (0.63) | CYP3A4CYP1A2CYP2D6CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924369-A | Phosphite group-containing carbazole polymerization inhibitor, preparation method and application thereof | 万华化学集团股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-110128570-B | Dendritic photosensitizer containing benzidine-based fragment, synthetic method and application | 郑州工程技术学院 | 2021-06-15 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| EP-2922596-B1 | HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES | NOVADRUG LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1856024-A1 | METHOD FOR PRODUCING SUBSTITUTED BIPHENYLS | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1567502-B1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006092429-A1 | METHOD FOR PRODUCING SUBSTITUTED BIPHENYLS | BASF AKTIENGESELLSCAHFT (DE) | 2006-09-08 | — | — | WO | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| EP-1567502-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | Wyeth (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6894061-B2 | Substituted dihydrophenanthridinesulfonamides | WYETH (US) | 2005-05-17 | — | — | US | disclosed |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | WYETH | 2004-08-26 | — | — | US | disclosed |
| WO-2004050631-A1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TDO2 4560/4885ADORA2A 239/4885ADORA1 259/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | TDO2 4560/4885ADORA2A 239/4885ADORA1 259/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TDO2 4560/4885ADORA2A 239/4885ADORA1 259/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | TDO2 4560/4885ADORA2A 497/4885ADORA1 545/4885 |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | TNNT2, TNNI3, SIRT5 | TDO2 2916/4885ADORA2A 4697/4885ADORA1 4694/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | TDO2 4575/4885ADORA2A 512/4885ADORA1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.